Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H14N4O4S |
Molecular Weight | 310.329 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1OC
InChI
InChIKey=PJSFRIWCGOHTNF-UHFFFAOYSA-N
InChI=1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)
Molecular Formula | C12H14N4O4S |
Molecular Weight | 310.329 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2013 |
0.14 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | FANSIDAR Approved UseFansidar is indicated for the treatment of acute, uncomplicated P. falciparum malaria for those patients in whom chloroquine resistance is suspected. Launch Date3.73075214E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
165.15 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23084093/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PYRIMETHAMINE |
SULFADOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
71.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11419747/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: PYRIMETHAMINE |
SULFADOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
60 mg/L |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: PYRIMETHAMINE |
SULFADOXINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21761.02 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23084093/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PYRIMETHAMINE |
SULFADOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
12394 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11419747/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: PYRIMETHAMINE |
SULFADOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
155.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11419747/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: PYRIMETHAMINE |
SULFADOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
200 h |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: PYRIMETHAMINE |
SULFADOXINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10% |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: PYRIMETHAMINE |
SULFADOXINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
500 mg 3 times / day single, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: single Dose: 500 mg, 3 times / day Co-administed with:: pyrimethamine Sources: |
unhealthy, adult Health Status: unhealthy Condition: malaria Age Group: adult Sex: unknown Sources: |
Disc. AE: Toxic epidermal necrolysis, Stevens-Johnson syndrome... AEs leading to discontinuation/dose reduction: Toxic epidermal necrolysis Sources: Stevens-Johnson syndrome (grade 5) Toxic epidermal necrolysis (grade 5) |
500 mg 3 times / day single, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: single Dose: 500 mg, 3 times / day Co-administed with:: pyrimethamine(25 mg/3 times/day) Sources: |
unhealthy, adult Health Status: unhealthy Condition: malaria Age Group: adult Sex: unknown Sources: |
Disc. AE: Stevens-Johnson syndrome... AEs leading to discontinuation/dose reduction: Stevens-Johnson syndrome Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Toxic epidermal necrolysis | Disc. AE | 500 mg 3 times / day single, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: single Dose: 500 mg, 3 times / day Co-administed with:: pyrimethamine Sources: |
unhealthy, adult Health Status: unhealthy Condition: malaria Age Group: adult Sex: unknown Sources: |
Stevens-Johnson syndrome | grade 5 Disc. AE |
500 mg 3 times / day single, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: single Dose: 500 mg, 3 times / day Co-administed with:: pyrimethamine Sources: |
unhealthy, adult Health Status: unhealthy Condition: malaria Age Group: adult Sex: unknown Sources: |
Toxic epidermal necrolysis | grade 5 Disc. AE |
500 mg 3 times / day single, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: single Dose: 500 mg, 3 times / day Co-administed with:: pyrimethamine Sources: |
unhealthy, adult Health Status: unhealthy Condition: malaria Age Group: adult Sex: unknown Sources: |
Stevens-Johnson syndrome | Disc. AE | 500 mg 3 times / day single, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: single Dose: 500 mg, 3 times / day Co-administed with:: pyrimethamine(25 mg/3 times/day) Sources: |
unhealthy, adult Health Status: unhealthy Condition: malaria Age Group: adult Sex: unknown Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients. | 2001 Dec |
|
Efficacy of mefloquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum infection in Machinga District, Malawi, 1998. | 2001 Dec |
|
The cost-effectiveness of antenatal malaria prevention in sub-Saharan Africa. | 2001 Jan-Feb |
|
Short report: differences in dihydrofolate reductase but not dihydropteroate synthase alleles in Plasmodium falciparum isolates from geographically distinct areas in Malaysia. | 2001 Jan-Feb |
|
Malaria diagnosis and treatment under the strategy of the integrated management of childhood illness (IMCI): relevance of laboratory support from the rapid immunochromatographic tests of ICT Malaria P.f/P.v and OptiMal. | 2001 Jul |
|
Therapeutic efficacy of sulphadoxine/pyrimethamine and susceptibility in vitro of P. falciparum isolates to sulphadoxine-pyremethamine and other antimalarial drugs in Malawian children. | 2001 Jun |
|
Cost-effectiveness of sulfadoxine-pyrimethamine for the prevention of malaria-associated low birth weight. | 2001 Mar-Apr |
|
History and importance of antimalarial drug resistance. | 2001 Nov |
|
Anemia of persistent malarial parasitemia in Nigerian children. | 2001 Oct |
|
[Danger of malaria self-treatment. Acute neurologic toxicity of mefloquine and its combination with pyrimethamine-sulfadoxine]. | 2001 Sep 29 |
|
Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. | 2002 |
|
Resistance of Plamodium falciparum to antimalarial drugs in Zaragoza (Antioquia, Colombia), 1998. | 2002 Apr |
|
Biofilm bacteria: formation and comparative susceptibility to antibiotics. | 2002 Apr |
|
Treatment of imported malaria in an ambulatory setting: prospective study. | 2002 Apr 13 |
|
High-performance liquid chromatographic assay for the simultaneous determination of sulfadoxine and pyrimethamine from whole blood dried onto filter paper. | 2002 Feb 5 |
|
[Frequency of persistent or transitory serologic negative values in infants with congenital toxoplasmosis. Experience of the Reims Toxoplasmosis Group (1980-1997)]. | 2002 Feb 9 |
|
Malaria: a rising incidence in the United States. | 2002 Jul |
|
Molecular epidemiology of malaria in Cameroon. X. Evaluation of PFMDR1 mutations as genetic markers for resistance to amino alcohols and artemisinin derivatives. | 2002 Jun |
|
African scientists discuss drug-resistant malaria. | 2002 Mar 2 |
|
Treatment of uncomplicated malaria in children in Guinea-Bissau with chloroquine, quinine, and sulfadoxine-pyrimethamine. | 2002 May-Jun |
|
Chloroquine and sulphadoxine-pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo-Dioulasso, Burkina Faso during a 3-year period 1998-2000. | 2002 Nov |
|
Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome. | 2002 Sep |
|
Intermittent administration of iron and sulfadoxine-pyrimethamine to control anaemia in Kenyan children: a randomised controlled trial. | 2002 Sep 21 |
Sample Use Guides
Treatment: adults should take 2 to 3 tablets (each tablet contains 500 mg sulfadoxine and 25 mg pyrimethamine) taken as a single dose. Prevention: adults should take 1 tablet weekly or 2 tablets once every two weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12499187
MIC99 value was found to be 30000 and 500000 ng/ml for FC27 strain of P. falciparum and K1 strain of P. falciparum, respectively when treated with sulfadoxine.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sun Dec 18 19:24:24 UTC 2022
by
admin
on
Sun Dec 18 19:24:24 UTC 2022
|
Record UNII |
88463U4SM5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000008048
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
||
|
NDF-RT |
N0000008048
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.5.3.1 (SUL/PYR)
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
||
|
WHO-VATC |
QJ01EW13
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
||
|
NDF-RT |
N0000175880
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
||
|
LIVERTOX |
NBK548044
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
||
|
NDF-RT |
N0000008048
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
||
|
WHO-VATC |
QJ01EQ13
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
M10308
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | Merck Index | ||
|
17134
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
DB01299
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
1626500
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
SUB10700MIG
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
2503
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
219-504-9
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
D013413
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
SULFADOXINE
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
2061
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
DTXSID6023608
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
759319
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
CHEMBL1539
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
SULFADOXINE
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | Description: A white or creamy white, crystalline powder; odourless. Solubility: Very slightly soluble in water; slightly soluble in ethanol (~750 g/l) TS and in methanol R; practically insoluble in ether R. Category: Antimalarial drug. Storage: Sulfadoxine should be kept in a well-closed container, protected from light. Definition: Sulfadoxine contains not less than 99.0% and not more than 101.0% of C12H14N4O4S, calculated with reference to the dried substance. | ||
|
9329
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
Sulfadoxine and Pyrimethamine
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
C47735
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
88463U4SM5
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
2447-57-6
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | |||
|
10173
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY | RxNorm | ||
|
88463U4SM5
Created by
admin on Sun Dec 18 19:24:25 UTC 2022 , Edited by admin on Sun Dec 18 19:24:25 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||